Loading stock data…
EVO
$2.80+0.06 (+2.19%)
After Hours$2.80+0.00 (+0.00%)· Last close Jun 29
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Evotec SE in the Healthcare sector is trading at $2.80 with a market capitalization of $963M. Wall Street consensus targets $5.11 (4 analysts), implying a +82.4% move over the next 12 months. The stock is currently 37% below its 52-week high of $4.42, remaining 13.0% below its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality, Altman Z in the distress zone. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +82.4% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $156.64M↓ | $253.27M↑ | $163.89M↓ | $171.24M↓ | $199.98M |
| Gross Profit | -$1.57M↓ | $78.46M↑ | -$62,000↓ | $8.59M↓ | $33.24M |
| Operating Income | -$46.42M↓ | $37.21M↑ | -$44.61M↓ | -$28.60M↓ | -$19.82M |
| Net Income | -$121.94M↓ | $14.62M↑ | -$43.09M↑ | -$43.48M↓ | -$31.58M |
Peer Comparison
JNJUNHPFE
Fundamentals
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just Evotec Biologics. The company is developing...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$962.56M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-27.71%
Volume
Today's trading volume
55,503
Recent News
Assessing Evotec (XTRA:EVT) Valuation After Recent Share Weakness And Ongoing Losses
Recent share performance and business snapshot Evotec (XTRA:EVT) drew investor attention after a mixed share performance, with the stock roughly flat in the past day, down over the past month, yet up over the past 3 months, against a backdrop of ongoing losses and modest revenue growth. See our latest analysis for Evotec. At around €4.93 per share, Evotec’s recent 7 day and year to date share price declines, alongside a 1 year total shareholder return fall of 31.1%, suggest sentiment has...
QuickLogic Posts Downbeat Q1 Results, Joins Resideo Technologies And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures were mixed this morning, with the Dow futures falling around 100 points on Wednesday. Shares of QuickLogic Corp (NASDAQ:QUIK) fell in pre-market trading after the company reported worse-than-expected first-quarter financial results. QuickLogic reported quarterly losses of 8 cents per share which missed the analyst consensus estimate of losses of 5 cents per share. The company reported quarterly sales of $5.051 million which missed the analyst consensus estimate of $5.508 milli
Evotec (EVO) Nominates First Preclinical Development Candidate from Almirall Alliance
Evotec SE (NASDAQ:EVO) is one of the 10 Best Penny Stocks to Buy Before They Explode. On May 4, 2026, Evotec SE (NASDAQ:EVO) announced the nomination of a small molecule preclinical development candidate from its multi-target drug discovery alliance with Almirall focused on medical dermatology. The program is aimed at developing new therapies for immune-mediated […]
European Market: Nokian Renkaat Oyj And Two Other Stocks That May Be Priced Below Estimated Value
In recent weeks, the European market has experienced modest gains amid easing geopolitical tensions and strong corporate earnings, although concerns over potential U.S. tariffs on EU goods have weighed on investor sentiment. As the European Central Bank signals potential rate hikes to combat rising inflation, investors are increasingly focused on identifying stocks that may be undervalued relative to their intrinsic value amidst these complex economic conditions.
European Stocks Estimated To Be Up To 30.8% Below Their Intrinsic Value
The European stock market recently experienced a volatile week, with modest gains in the pan-European STOXX Europe 600 Index, as investor sentiment was buoyed by easing geopolitical tensions and strong corporate earnings. However, looming threats of increased tariffs from the U.S. added pressure to markets. In this context, identifying undervalued stocks becomes crucial for investors seeking opportunities that are potentially trading below their intrinsic value amidst fluctuating market...